EA201790380A1 - Ингибиторы mk2 и их применения - Google Patents

Ингибиторы mk2 и их применения

Info

Publication number
EA201790380A1
EA201790380A1 EA201790380A EA201790380A EA201790380A1 EA 201790380 A1 EA201790380 A1 EA 201790380A1 EA 201790380 A EA201790380 A EA 201790380A EA 201790380 A EA201790380 A EA 201790380A EA 201790380 A1 EA201790380 A1 EA 201790380A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
applications
compositions
methods
present
Prior art date
Application number
EA201790380A
Other languages
English (en)
Other versions
EA037299B1 (ru
Inventor
Мэттью Дэвид Александр
Клаудио Чуаки
Джон Малона
Джозеф Джон Макдоналд
Айк Ни
Децян Ню
Расселл К. Петтер
Джасвиндер Сингх
Читтари Пабба
Original Assignee
Селджен Кар Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджен Кар Ллс filed Critical Селджен Кар Ллс
Publication of EA201790380A1 publication Critical patent/EA201790380A1/ru
Publication of EA037299B1 publication Critical patent/EA037299B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

В настоящем изобретении предложены соединения, их композиции и способы их применения.
EA201790380A 2014-09-17 2015-09-16 Ингибиторы mk2 и их применения EA037299B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
EA201790380A1 true EA201790380A1 (ru) 2017-08-31
EA037299B1 EA037299B1 (ru) 2021-03-05

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790380A EA037299B1 (ru) 2014-09-17 2015-09-16 Ингибиторы mk2 и их применения

Country Status (30)

Country Link
US (5) US9458175B2 (ru)
EP (2) EP3193611B1 (ru)
JP (3) JP6556225B2 (ru)
KR (1) KR102457848B1 (ru)
CN (1) CN106998692B (ru)
AU (1) AU2015317741B2 (ru)
BR (1) BR112017005266B1 (ru)
CA (1) CA2961607C (ru)
CL (1) CL2017000576A1 (ru)
CO (1) CO2017003279A2 (ru)
CY (1) CY1124215T1 (ru)
DK (1) DK3193611T3 (ru)
EA (1) EA037299B1 (ru)
EC (1) ECSP17023281A (ru)
ES (1) ES2874561T3 (ru)
HR (1) HRP20210529T1 (ru)
HU (1) HUE054347T2 (ru)
IL (1) IL251051B (ru)
LT (1) LT3193611T (ru)
MA (1) MA40534B1 (ru)
MX (2) MX2017003359A (ru)
NZ (1) NZ730603A (ru)
PL (1) PL3193611T3 (ru)
PT (1) PT3193611T (ru)
RS (1) RS62017B1 (ru)
SA (1) SA517381115B1 (ru)
SG (2) SG11201701861RA (ru)
SI (1) SI3193611T1 (ru)
TW (1) TWI744217B (ru)
WO (1) WO2016044463A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968339A4 (en) 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
KR102457848B1 (ko) 2014-09-17 2022-10-25 셀젠 카르 엘엘씨 Mk2 억제제 및 이의 용도
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170203A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
WO2018170199A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
US20230130766A1 (en) * 2020-02-14 2023-04-27 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
EP4185382A1 (en) * 2020-07-24 2023-05-31 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20100031619A (ko) 2007-07-16 2010-03-23 노파르티스 아게 Ｍｋ２ 억제제로서 유용한 헤테로시클릭 화합물
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2013124040A1 (en) 2012-02-22 2013-08-29 Merck Patent Gmbh Liquid crystalline medium
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2898421A4 (en) * 2012-09-24 2016-07-13 Claremont Speede CONTROLLED DATA ACCESS AND METHOD AND SYSTEM FOR CLEARING DATA THROUGH A MOBILE TRANSMITTER
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP2968339A4 (en) 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
KR102457848B1 (ko) 2014-09-17 2022-10-25 셀젠 카르 엘엘씨 Mk2 억제제 및 이의 용도
JP2018502860A (ja) 2015-01-08 2018-02-01 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害ペプチド製剤
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4185382A1 (en) 2020-07-24 2023-05-31 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
US10577380B2 (en) 2020-03-03
US9790235B2 (en) 2017-10-17
US10253040B1 (en) 2019-04-09
SG11201701861RA (en) 2017-04-27
CA2961607A1 (en) 2016-03-24
US20190375762A1 (en) 2019-12-12
SI3193611T1 (sl) 2021-08-31
IL251051A0 (en) 2017-04-30
MX2017003359A (es) 2017-11-22
NZ730603A (en) 2024-02-23
JP6556225B2 (ja) 2019-08-07
US20160075720A1 (en) 2016-03-17
MA40534A (fr) 2016-03-24
MX2020005213A (es) 2020-08-20
RS62017B1 (sr) 2021-07-30
PL3193611T3 (pl) 2021-10-04
EA037299B1 (ru) 2021-03-05
KR20170063734A (ko) 2017-06-08
PT3193611T (pt) 2021-05-28
KR102457848B1 (ko) 2022-10-25
CL2017000576A1 (es) 2017-12-01
US9458175B2 (en) 2016-10-04
BR112017005266A2 (pt) 2017-12-12
DK3193611T3 (da) 2021-05-10
US20210053984A1 (en) 2021-02-25
CN106998692B (zh) 2020-09-08
JP7375072B2 (ja) 2023-11-07
JP2017529367A (ja) 2017-10-05
EP3193611A2 (en) 2017-07-26
JP2019194236A (ja) 2019-11-07
CA2961607C (en) 2023-03-28
CN106998692A (zh) 2017-08-01
LT3193611T (lt) 2021-08-25
IL251051B (en) 2019-11-28
ECSP17023281A (es) 2017-06-30
CY1124215T1 (el) 2022-05-27
AU2015317741A1 (en) 2017-04-20
US11584757B2 (en) 2023-02-21
TWI744217B (zh) 2021-11-01
US20170114073A1 (en) 2017-04-27
SG10201902326XA (en) 2019-04-29
HUE054347T2 (hu) 2021-08-30
CO2017003279A2 (es) 2017-09-29
TW201617351A (zh) 2016-05-16
EP3193611A4 (en) 2018-02-28
BR112017005266B1 (pt) 2022-11-01
EP3912981A1 (en) 2021-11-24
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
SA517381115B1 (ar) 2021-03-09
WO2016044463A2 (en) 2016-03-24
AU2015317741B2 (en) 2020-01-16
JP2022078315A (ja) 2022-05-24
WO2016044463A3 (en) 2016-09-01
MA40534B1 (fr) 2021-04-30
EP3193611B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
BR112016018521A2 (pt) composição, e, kit.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201790173A1 (ru) Антитела, связывающие axl
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
TR201901228T4 (tr) Vortioksetin piroglutamat.
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
PH12017501864A1 (en) Compositions and methods for treating autism

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM